Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Account Payables (2021 - 2025)

Krystal Biotech's Change in Account Payables history spans 5 years, with the latest figure at -$183000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 69.04% year-over-year to -$183000.0; the TTM value through Dec 2025 reached $826000.0, down 18.3%, while the annual FY2025 figure was $826000.0, 18.3% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$183000.0 at Krystal Biotech, up from -$4.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.1 million in Q2 2025 and bottomed at -$4.0 million in Q3 2025.
  • The 5-year median for Change in Account Payables is $99000.0 (2023), against an average of $59700.0.
  • The largest annual shift saw Change in Account Payables surged 579.44% in 2024 before it plummeted 4517.58% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $937000.0 in 2021, then tumbled by 200.11% to -$938000.0 in 2022, then soared by 76.33% to -$222000.0 in 2023, then tumbled by 166.22% to -$591000.0 in 2024, then skyrocketed by 69.04% to -$183000.0 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Change in Account Payables are -$183000.0 (Q4 2025), -$4.0 million (Q3 2025), and $4.1 million (Q2 2025).